Viridian Therapeutics Quarterly Balance Sheet
NASDAQ: VRDNHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Viridian Therapeutics financial position
As of Jun 30, 2026, Viridian Therapeutics reported total assets of $1.10 billion, up 88.4% from a year earlier against total liabilities of $435.1 million. Shareholders' equity stood at $662.1 million, or 60.3% of assets. The company held $165.0 million in cash and equivalents against $113.6 million of debt, a net cash position of $51.3 million.
The current ratio (current assets divided by current liabilities) was 16.95, meaning short-term assets cover obligations due within a year. Debt-to-equity was 0.17.
Summary generated from market data by MetaCap's automated system. Methodology
Viridian Therapeutics balance sheet (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 164.99M | 176.35M | 212.38M | 169.65M | 117.32M | 116.22M | 99.59M | 200.32M | 107.67M | 91.64M | 102.83M | 111.60M |
| Short-Term Investments | 816.54M | 585.84M | 662.27M | 321.25M | 446.03M | 520.42M | 617.99M | 552.92M | 463.70M | 521.55M | 374.54M | 201.41M |
| Total Current Assets | 1.08B | 784.74M | 894.23M | 571.91M | 578.75M | 657.24M | 738.46M | 767.36M | 581.66M | 626.82M | 486.48M | 323.84M |
| Property, Plant & Equipment | 2.77M | 1.13M | 1.23M | 1.13M | 1.09M | 1.16M | 1.24M | 1.29M | 1.51M | 1.53M | 1.67M | 1.80M |
| Intangible Assets | 10.00M | — | 0 | — | — | — | — | — | — | — | — | — |
| Total Assets | 1.10B | 789.02M | 899.42M | 577.14M | 582.32M | 660.98M | 742.40M | 771.90M | 585.66M | 630.38M | 490.42M | 328.76M |
| Accounts Payable | 8.65M | 13.31M | 8.68M | 10.06M | 8.52M | 3.89M | 2.14M | 6.34M | 3.14M | 2.68M | 2.24M | 3.73M |
| Short-Term Debt | — | — | — | — | 8.44M | — | 0 | — | 2.96M | — | 0 | — |
| Total Current Liabilities | 63.79M | 51.80M | 70.70M | 50.70M | 52.59M | 33.73M | 47.87M | 41.36M | 36.76M | 26.13M | 26.64M | 23.25M |
| Long-Term Debt | 113.64M | 36.09M | 34.24M | 20.89M | 12.35M | 20.68M | 20.58M | 20.52M | 17.49M | 20.33M | 20.20M | 20.00M |
| Total Liabilities | 435.14M | 153.01M | 177.25M | 74.17M | 67.16M | 56.51M | 70.76M | 64.40M | 56.33M | 47.85M | 48.40M | 45.18M |
| Shareholders' Equity | 662.10M | 636.01M | 722.17M | 502.97M | 515.17M | 604.47M | 671.64M | 707.50M | 529.34M | 582.53M | 442.02M | 283.58M |
| Retained Earnings | -1.57B | -1.44B | -1.34B | -1.22B | -1.18B | -1.08B | -995.86M | -916.13M | -839.44M | -774.45M | -725.91M | -659.05M |
| Total Debt | 113.64M | 36.09M | 34.24M | 20.89M | 20.79M | 20.68M | 20.58M | 20.52M | 20.45M | 20.33M | 20.20M | 20.00M |
| Net Cash (Debt) | 867.89M | 726.09M | 840.41M | 470.01M | 542.57M | 615.95M | 697.00M | 732.72M | 550.91M | 592.86M | 457.17M | 293.01M |
| Shares Outstanding | 113.24M | 102.46M | 101.83M | 82.23M | 81.65M | 81.59M | 80.99M | 79.18M | 63.88M | 63.80M | 53.99M | 43.70M |
This table shows 12 quarterly periods of Viridian Therapeutics's balance sheet, from Q2 2026 back to Q3 2023, across 19 line items including cash & equivalents, short-term investments, receivables. Values in USD; B = billions, M = millions. Fiscal periods follow VRDN's reporting calendar. What is a balance sheet?